BioPharma Dive January 30, 2025
The genetic testing company ended last year with $79 million and told investors it will need to raise money to fund its operations and financial commitments.
Dive Brief:
- 23andMe said Tuesday it is exploring “strategic alternatives,” which could include the sale of the company, a business combination or restructuring.
- The genetic testing company ended 2024 with $79 million and told investors it will need to raise money to fund its operations and financial commitments.
- CEO Anne Wojcicki tried to take the company private last year but the board rejected the proposal. The independent board directors later resigned, citing differences with Wojcicki on 23andMe’s future. The company also recently laid off more than 200 people in a restructuring that ended...
Today's Sponsors
Today's Sponsor